Insurers Say Mallinckrodt Sales Strategy Cost Them $320M

By Rick Archer · November 12, 2021, 7:42 PM EST

A pair of insurers seeking antitrust damages from drugmaker Mallinckrodt over the sales of its Acthar gel put their expert witnesses before a Delaware bankruptcy judge on Friday, claiming they overpaid...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Mallinckrodt plc

Case Number

1:20-bk-12522

Court

Delaware

Nature of Suit

Date Filed

October 12, 2020